MTCR
Metacrine, Inc. Common Stock
MTCR
MTCR
Delisted
MTCR was delisted on the 8th of February, 2023.
About: Metacrine Inc is a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases. Its program targets the farnesoid X receptor, or FXR, which is central to modulating liver and GI diseases. Its FXR product candidates include MET409 and MET642.
Employees: 10
Charts implemented using
Lightweight Charts™